Encysive, Barr in patent row over Argatroban

01/2/2008 | CNNMoney

Encysive Pharmaceuticals' patent for Argatroban, an injectable blood-clotting treatment, is under challenge. Barr Pharmaceuticals claims its generic version of Argatroban would infringe an existing patent, but contends that Encysive's patent is invalid. Last week, Encysive announced it was trying to keep Barr from obtaining FDA approval for the generic version for 30 months.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC